Celldex Therapeutics Statistics
Total Valuation
CLDX has a market cap or net worth of $2.42 billion. The enterprise value is $1.60 billion.
| Market Cap | 2.42B |
| Enterprise Value | 1.60B |
Important Dates
The next estimated earnings date is Tuesday, August 6, 2024, after market close.
| Earnings Date | Aug 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CLDX has 65.91 million shares outstanding. The number of shares has increased by 24.69% in one year.
| Shares Outstanding | 65.91M |
| Shares Change (YoY) | +24.69% |
| Shares Change (QoQ) | +13.07% |
| Owned by Insiders (%) | 0.29% |
| Owned by Institutions (%) | 107.16% |
| Float | 65.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 399.02 |
| Forward PS | 830.04 |
| PB Ratio | 2.89 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 263.69 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 31.77, with a Debt / Equity ratio of 0.00.
| Current Ratio | 31.77 |
| Quick Ratio | 31.44 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -32.30% and return on invested capital (ROIC) is -19.35%.
| Return on Equity (ROE) | -32.30% |
| Return on Assets (ROA) | -30.30% |
| Return on Capital (ROIC) | -19.35% |
| Revenue Per Employee | $37,950 |
| Profits Per Employee | -$905,475 |
| Employee Count | 160 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.84% in the last 52 weeks. The beta is 1.58, so CLDX's price volatility has been higher than the market average.
| Beta (5Y) | 1.58 |
| 52-Week Price Change | -0.84% |
| 50-Day Moving Average | 36.85 |
| 200-Day Moving Average | 36.18 |
| Relative Strength Index (RSI) | 47.73 |
| Average Volume (20 Days) | 714,556 |
Short Selling Information
The latest short interest is 6.99 million, so 10.60% of the outstanding shares have been sold short.
| Short Interest | 6.99M |
| Short Previous Month | 6.43M |
| Short % of Shares Out | 10.60% |
| Short % of Float | 10.63% |
| Short Ratio (days to cover) | 8.95 |
Income Statement
In the last 12 months, CLDX had revenue of $6.07 million and -$144.88 million in losses. Loss per share was -$2.86.
| Revenue | 6.07M |
| Gross Profit | 6.07M |
| Operating Income | -162.68M |
| Pretax Income | -144.88M |
| Net Income | -144.88M |
| EBITDA | -141.82M |
| EBIT | -144.88M |
| Loss Per Share | -$2.86 |
Balance Sheet
The company has $823.85 million in cash and $2.11 million in debt, giving a net cash position of $821.73 million or $12.47 per share.
| Cash & Cash Equivalents | 823.85M |
| Total Debt | 2.11M |
| Net Cash | 821.73M |
| Net Cash Per Share | $12.47 |
| Equity (Book Value) | 838.61M |
| Book Value Per Share | 12.72 |
| Working Capital | 809.03M |
Cash Flow
In the last 12 months, operating cash flow was -$119.36 million and capital expenditures -$1.58 million, giving a free cash flow of -$120.94 million.
| Operating Cash Flow | -119.36M |
| Capital Expenditures | -1.58M |
| Free Cash Flow | -120.94M |
| FCF Per Share | -$2.05 |
Margins
Gross margin is 100.00%, with operating and profit margins of -2,679.17% and -2,385.97%.
| Gross Margin | 100.00% |
| Operating Margin | -2,679.17% |
| Pretax Margin | -2,385.97% |
| Profit Margin | -2,385.97% |
| EBITDA Margin | -2,335.62% |
| EBIT Margin | -2,385.97% |
| FCF Margin | -1,991.72% |
Dividends & Yields
CLDX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.69% |
| Shareholder Yield | -24.69% |
| Earnings Yield | -5.98% |
| FCF Yield | -4.99% |
Analyst Forecast
The average price target for CLDX is $66.00, which is 79.54% higher than the current price. The consensus rating is "Buy".
| Price Target | $66.00 |
| Price Target Difference | 79.54% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 126.86% |
| EPS Growth Forecast (5Y) | -8.56% |
Stock Splits
The last stock split was on February 11, 2019. It was a reverse split with a ratio of 1:15.
| Last Split Date | Feb 11, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
CLDX has an Altman Z-Score of 46.35 and a Piotroski F-Score of 4.
| Altman Z-Score | 46.35 |
| Piotroski F-Score | 4 |